NEW YORK (GenomeWeb) – UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.

Under the terms of the agreement, the companies will market Angle's Parsortix system for harvesting CTCs alongside Qiagen's liquid biopsy product portfolio, including its next-generation sequencing, PCR, single-cell analysis, and bioinformatics products.

The companies will initially focus on prostate and breast cancer research applications, Angle said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.